5Yang CJ, Hwang JJ, Wang TH, et al. Clinical and radiographic presentations of pulmonary eryptococcosis in immunocompetent patients. Scand J Infect Dis, 2006,38:788.
6Salyer WR, Salyer DC, Baker RD. Primary complex of Cryptococcus and pulmonary lymph nodes. J Infect Dis, 1974,130:7.
9Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated eryptocoecal meningitis. The NIAID Mycoses Study Group and the AIDS Clinieat Trials Group. N Engl J Med, 1992, 326 : 83.
10Berry AJ, Rinaldi MG, Graybill JR. Use of high-dose flueonazole as salvage therapy for eryptococcal meningitis in patients with AIDS. Antimierob Agents Chemother, 1992,36:690.
4National Committee for Clinical Laboratory Standards.2002.Reference method for broth dilution antifungal susceptibility testing of filamentous fungi.Approved standard M38-A [ J ].National Committee for Clinical Laboratory Standards,Wayne,Pa.
5Pfaller MA,Boyken L,Hollis R J,et al.Susceptibilities of clinical Isolates of Candida Species,Cryptococcus neoformans,and Aspergillus species to itraconazole:global survey of 9,359 isolates tested by Clinical and Laboratory Standards Institute broth microdilution methods [ J ].J of Clin Microbiol,2005,43:3807-38100.
6Hiemenz JW, Walsh TJ. Lipid formulations of amphotericin B: recent progress and future directions[J]. Clin Inf Dis, 1996,22(suppl 2): S133-144
7White MH, Anaissie EJ, Kusne S, et al. Amphotericin B colloidal dispersion vs amphotericin B as therapy for invasive aspergillosis[J]. Clin Inf Dis, 1997, 24: 635-642
8Leenders A, Reiss P, Portegies P et al. Liposomal amphotericin B( AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis[J]. AIDS, 1997, 11: 1463-1471
9Bellmann R, Egger P. Wiedermann CJ. Differences in pharmacokinctics of amphotericin B lipid formulations despite clinical equivalence[J]. Clin Inf Dis, 2003, 36: 1500-1501
10Arikan S, Rex JH. New agents for the treatment of systemic fungal infections-current status[J]. Expert Opin. Emerging Drugs, 2002,7:3-32
